Autoimmune hemolytic anemia (AIHA) is a rare immune disease. With our company's profound expertise in AIHA research, we are well-equipped to offer tailored solutions and comprehensive support to facilitate your research process from AIHA therapy development to therapy commercialization.
AIHA is a rare immune disorder characterized by the body's immune system mistakenly attacking its own red blood cells. AIHA occurs when the immune system produces antibodies that target and destroy red blood cells, leading to a decrease in the number of circulating red blood cells, a condition known as anemia. AIHA is divided into warm autoimmune hemolytic anemia (wAIHA) and cold autoimmune hemolytic anemia (cAIHA).
| Disease Types | Characteristic | Incidence | Proportion |
|---|---|---|---|
| Warm Autoimmune Hemolytic Anemia (wAIHA) | Presence of IgG antibodies that bind to red blood cells at normal body temperature | 5-10/1,000,000 | Most common type |
| Cold Autoimmune Hemolytic Anemia (cAIHA) | Presence of IgM autoantibodies that bind to red blood cells at lower temperatures | 0.45-1.9/1,000,000 | Relatively rare type |
The pathogenesis of AIHA involves a complex interplay between the immune system and red blood cells. In primary AIHA, the exact cause is unknown, and the immune system mistakenly recognizes self-antigens on red blood cells as foreign and mounts an immune response against them. Secondary AIHA, on the other hand, is associated with underlying conditions such as viral infections, autoimmune diseases, medications, or blood cancers.
Fig. 1 Pathogenic mechanisms of red blood cell destruction. (Barcellini, Wilma, et al.,2020)Autoantibodies
B cells are a subset of white blood cells that play a crucial role in the production of autoantibodies. Rituximab targets CD20 and effectively depletes B cells, reducing the production of autoantibodies and improving red blood cell survival. Rituximab has shown promising results in the therapeutics of AIHA.
Immune Pathways
Inhibition of specific immune pathways, such as the B-cell receptor signaling pathway or the complement cascade, can attenuate the immune response against red blood cells. Eculizumab targets complement protein C5, inhibits the complement cascade, and prevents complement activation-mediated destruction of red blood cells.
Drawing upon our deep expertise in biotechnology and extensive experience in the industry, our company offers all-encompassing solutions for diagnostic and therapeutic research dedicated to AIHA.
| Induced Models | ||
|---|---|---|
| At our company, our scientists induce AIHA-like symptoms in animals by intraperitoneally injecting them with antibodies against red blood cells, such as anti-erythrocyte antibodies or anti-erythrocyte autoantibodies, which destroy red blood cells. In addition, we can also induce AIHA models through certain chemical drugs. | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Utilizing cutting-edge gene manipulation technology, our researchers achieved the replication of specific AIHA-associated mutations in animal models, resulting in the successful generation of AIHA genetically engineered models. | ||
| Optional Models |
|
|
| Optional Species | New Zealand black (NZB) Mice, Rats, Dogs, Cats Non-human Primates (Rhesus Macaques), Others | |
No matter what research stage you are at, we can provide you with corresponding research services. If you are interested in our services, please feel free to contact us for more details and quotation information for related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)